### **RESPONSIBILITY ALLOCATION MATRIX**

Investigator:

The following schedule sets out the agreed allocation of study-related duties between the Sponsor (add name as applicable Royal Devon University Healthcare NHS Foundation Trust or University of Exeter), the Chief Investigator (CI) and the Clinical Trials Unit (CTU) (if applicable) for the (add name) study.

L= Lead responsibility X = Participating N/A = Not Applicable

Task	Α	Illocated to:		Comments
	Sponsor Add Royal Devon/UoE	CI	CTU Add Name or delete as applic. Further columns may be added	
KEY DOCUMENT PREPARATION				
Protocol writing		eg L	X	
Protocol review				
Ensure protocol is compliant with applicable regulations and guidelines				
Protocol amendment writing				
Protocol amendment review				
Participant Information Sheet / Consent Form writing				
Participant Information Sheet / Consent Form review				
Case Report Form (CRF) design (paper or e-CRF)				
CRF review (including updates) and approval. (If eCRF validation of e-CRF)				
CRF printing				
eCRF / CRF training				
Preparation of study-specific SOPs/work instructions				
Study-specific SOPs/work instructions review				
Preparation of instructional manuals including amendments (eg lab manual, randomisation manual)				
Instructional manual review				
Preparation of other study-specific documents (eg recruitment materials, pocket cards etc)				
Other study-specific documents review				

сті	IDV	TIT	ıF.

### **RESPONSIBILITY ALLOCATION MATRIX**

<u>FINANCE</u>	
Negotiation of study budget (identification of activities)	
Cost attribution	
Maintain oversight of trial budget	
Provide financial reports to funder	
AGREEMENTS	
Ensure collaboration agreements are in place	
Selection, negotiation, management of vendors (eg central labs, drug suppliers, couriers)	
Ensure 3 <sup>rd</sup> party agreements are in place (name)	
Ensure insurance and indemnity arrangements are in place	
Ensure all Sponsor agreements are in place prior to commencement	
Provide and obtain sign off for Site Agreements (model or Organisation Information Document/OID) to participating sites	
APPROVALO	
APPROVALS	
Portfolio adoption application	
Preparation of initial Health Research Authority (HRA) & Research Ethics Committee (REC) application	
Review of initial HRA & REC application	
Submission of initial HRA & REC application	
Preparation of amendments (non-substantial and substantial)	
Review of amendments (non-substantial and substantial)	
Judge substantiality of amendments	
Submission of amendments to HRA, REC (as applicable)	
Ensure REC approvals (including amendments) are in place	
Preparation of initial MHRA Clinical Trials Authorisation (CTA) application	
Review of initial MHRA CTA application	
Submission of initial MHRA CTA application	

CТ	ГΙ	יחו	7 7	гіт	-I I	⊏.

### **RESPONSIBILITY ALLOCATION MATRIX**

Preparation of amendments to CTA application						
Review of amendments to CTA application						
Submission of amendments to CTA application						
Obtain EUDRACT number and completion of EUDRACT application form						
Ensure trial is registered (eg ClinicalTrials.gov) before recruitment starts. Update registration as necessary						
Provide local document pack to sites and R&D offices						
Provide HRA approval & updated documents to sites						
Ensure CI has R&D approval in place						
Confirm R&D approvals and agreements are in place and issue 'green light' for recruitment can begin						
<b>INVESTIGATIONAL MEDICINAL PRODUCT (IMP) &amp; TRI</b>	AL SUPPLIES	MANAGEME	NT			
IMP procurement (including necessary import licenses if applicable)						
IMP labelling and package design (Including translation if required)						
Trial ancillaries (eg needles, syringes, infusion bags etc) purchase, storage and distribution						
Develop IMP distribution system						
Storage of IMP and distribution to sites						
Requests for resupply						
Receipt and storage of IMP at sites						
Dispensing of IMP to participants						
Maintain drug accountability						
Manage IMP excursions (eg temperature, integrity)					 	
Implement product recall process						
Preparation of Investigator Brochure (IB) or sourcing Summary of Product Characteristics (SmPC)						
Distribution of IB /SmPC and amendments						
Preparation and management of randomisation list						
SAFETY REPORTING						
Development of Adverse Event (AE) & Serious Adverse Event (SAE) reporting plan						

СТІ	IDA	TIT	IF۰

# **RESPONSIBILITY ALLOCATION MATRIX**

·	<del>_</del>	
Provide Investigator training on safety reporting responsibilities		
Receipt SAE's from investigators and follow up as required		
Review SAE's for accuracy and completeness		
Maintain safety database		
Review all SAE's (Assess seriousness, causality and severity)		
Review all SAE's for relatedness		
Review all SAE's for expectedness		
Compile and send periodic reports of all reported SAEs to sponsor		
Reporting of adverse reactions that affect the health and safety of participants (eg Suspected Unexpected Serious Adverse Reactions/SUSARs)		
Unblinding process initiation for potential SUSARs		
Reporting unblinded SUSAR to MHRA, REC and Data Monitoring Committee (DMC)		
Notify Principal Investigators (PI's) of any SUSAR		
Compile & send annual safety report to MHRA, Sponsor and REC		
Ensure emergency unblinding procedures are in place		
MONITORING, COMPLIANCE AND QUALITY ASSURAN	<u>CE</u>	
Provide Trial Master File (TMF) template		
Compile and maintain TMF		
Perform and review risk assessment of trial to include proposed intervention		
Perform and review risk assessment of trial management		
Generate and review Monitoring Plan		
Design of monitoring process and provide template materials / training to monitoring personnel		
Perform central data monitoring		
Generate data queries		
Resolve data queries		
Perform investigator site monitoring visits as dictated by monitor plan and compile monitoring reports		

сті	IDV	TIT	ıF.

# **RESPONSIBILITY ALLOCATION MATRIX**

	<del>,</del>		
Maintain log of all Investigator site monitoring visits			
Maintain file of all monitoring reports			
Perform trial audits as required			
Maintain log of protocol / GCP non-compliance reports			
Record serious breaches			
Adjudge whether violations constitute serious breach			
Report serious breaches to REC & MHRA as applicable			
		<u>.</u>	
TRIAL OVERSIGHT (MEETINGS, REPORTS)			
Provide day to day management of trial			
Monitor on-going safety and ethics of trial			
Formalise & arrange Trial Management Group (TMG)			
Prepare and circulate minutes of TMG			
Identify and appoint Trial Steering Committee (TSC) and Data Monitoring Committee (DMC) members			
Prepare TSC and DMC charters			
Arrange TSC & DMC meetings			
Prepare and circulate minutes of TSC and DMC			
Provide progress reports to DMC & TSC			
Provide reports and attend Sponsor Oversight Meetings on request			
Provide annual progress reports to Regulatory Authorities (REC, MHRA) and Sponsor			
Provide annual reports to funder as required			
GENERAL TRIAL MANAGEMENT AND TRAINING			
Trial Site selection (distribution of Expression of Interests/ EOIs, feasibility assessment)			
Provide study-specific training to staff			
Site Initiation			
Day-to-day correspondence with Investigators' research teams			
Specify content of TMF, Investigator Site File (ISF) and Pharmacy File			
Collate and maintain TMF			

STUDY TITLE:	R&D NO:	RESPONSIBILITY ALLOCATION MATRIX	Investigator:
Collate and provide Id	SF and Pharmacy File to sites		
Maintain ISF and pha	armacy file		
Distribution of trial do	ocumentation to sites		
Newsletters			
DATA MANAGEMEN	<u>NT</u>		
Build and test study of	database		
Database validation			
Maintain study datab	ase		
Develop Data Manag	gement Plan		
Review Data Manage	ement Plan		
Trial data receipt from	n sites and query management		
Data locking prior to	analysis		
<u>STATISTICS</u>			
Create and revise Starequired	atistical Analysis Plan (SAP) as		
Approval of SAP			
	alysis (including interim analysis, resentations & publications)		
END OF TRIAL AND	DISEMINATION		
Send end of study no	otification to REC, MHRA		
Surplus IMP destruct	ion authorisation		
Close out visit and ar	rchive notification to sites		
Archive TMF, ISF and	d CRFs		
Develop Publication	Plan		
Prepare trial results f	or publication		

Prepare and submit trial results reports to regulatory bodies in a timely fashion (eg MHRA, REC)

Post study results on registry in a timely fashion (EUDRACT, ClinicalTrials.gov)

Inform participants of results

STUDY TITLE: R&D NO:

**RESPONSIBILITY ALLOCATION MATRIX** 

# **RESPONSIBILITY ALLOCATION MATRIX**

Investigator:

SIGNATURE PAGE

Name (Print) Position Signature Date

Signed by Chief Investigator

Name (Print) Position Signature Date

Signed by CTU (delete if not applicable)

Name (Print) Position Signature Date